Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Why Healius (HLS) shares jumped 15% today

The Healius Ltd (ASX:HLS) share price was trading 15% higher on Wednesday following the release of its 2020 half-year financial report.

For context, the broader Australian share market or S&P/ASX 200 (ASX: XJO) was trading at 6735.1, down 1.92%.

Healius, formerly known as Primary Health Care Limited (ASX: PRY), is a healthcare business that provides pathology, diagnostic imaging, medical centres and low-cost fertility services, such as IVF. It operates across thousands of sites Australia wide.

Featured video:  there’s profit, then there’s profit

In the Rask video above, Owen explains the difference between ‘underlying’ or ‘normalised’ results and ‘statutory’ results. Knowing the difference between these two numbers is essential to understanding a financial report. Take one of our free finance courses by clicking here.

Healius – Key Results

This period Last period Change
Revenue 945.1 878.9 7.53%
Profit 66.3 20.4 225%
Cash flow 129.3 55.6 132.55%
Dividends (cents) 2.6 3.8 -31.58%

Source: Healius Ltd announcements; author calculations, AUD millions unless otherwise stated.

As can be seen above, the company’s revenue came in at $945.1 million, up $66.2 million over the prior corresponding period.

“The performance across all of our divisions is starting to reflect the efficiencies from our organisational redesign and cost savings initiatives, known as the Sustainable Improvement Program,” CEO Dr Malcolm Parmenter said.

“A mix of volume and fee increases assisted Pathology to achieve above-market revenue growth while Imaging benefitted from new and expanded sites, including the Northern Beaches Hospital in Sydney and the Australian Defence Force Health Services contract in partnership with Bupa.”

Healius’ profit was $66.3 million, up $45.9 million. However, on an underlying profit basis, Healius’ net profit (NPAT) came in at $42.1 million, which was up around 7.6% from last year.

On the cash flow statement, which is an important financial statement since it represents the underlying health of a business, operating cash flow was $129.3 million.

Looking at the different segments, Pathology, Medical Centres and Imaging all showed year-over-year revenue growth. However, Pathology remains Healius’ most important business line, accounting for around two-thirds of operating profit.

Looking towards the future Healius expects to achieve underlying profit between $96 million and $102 million for the full year. “To achieve the top of the range, our second half volumes will require improvements in pathology in line with last year,” Parmenter added.

Healius shares were last seen trading at $3.2, giving the company a market capitalisation more than $2 billion according to Google Finance.

[ls_content_block id=”14948″ para=”paragraphs”]

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Skip to content